Brainstorm Cell Therapeutics (BCLI) Competitors

$0.69 +0.00 (+0.57%)

As of 05/14/2026 03:36 PM Eastern

BCLI vs. SNTI, LSTA, BCTX, KYNB, and TVGN

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? MarketBeat compares Brainstorm Cell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainstorm Cell Therapeutics include Senti Biosciences (SNTI), Lisata Therapeutics (LSTA), Briacell Therap (BCTX), Kyntra Bio (KYNB), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.

How does Brainstorm Cell Therapeutics compare to Senti Biosciences?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Senti Biosciences had 6 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 7 mentions for Senti Biosciences and 1 mentions for Brainstorm Cell Therapeutics. Senti Biosciences' average media sentiment score of 0.94 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senti Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Senti Biosciences	N/A	-301.48%	-90.03%

Senti Biosciences has a consensus target price of $8.50, indicating a potential upside of 717.31%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.90	N/A
Senti Biosciences	$20K	1,619.28	-$61.44M	-$3.19	N/A

Brainstorm Cell Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

Summary

Senti Biosciences beats Brainstorm Cell Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Lisata Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.90	N/A
Lisata Therapeutics	$170K	165.05	-$16.59M	-$1.86	N/A

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 387.01%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Lisata Therapeutics had 2 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for Brainstorm Cell Therapeutics. Lisata Therapeutics' average media sentiment score of 1.41 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainstorm Cell Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Summary

Lisata Therapeutics beats Brainstorm Cell Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

In the previous week, Briacell Therap had 5 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for Briacell Therap and 1 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 beat Briacell Therap's score of -0.37 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.90	N/A

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Briacell Therap has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Brainstorm Cell Therapeutics beats Briacell Therap on 6 of the 11 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 2.0% of Kyntra Bio shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kyntra Bio has higher revenue and earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$7.44M	3.81	$183.45M	$40.46	0.17
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.90	N/A

Kyntra Bio has a net margin of 2,199.13% compared to Brainstorm Cell Therapeutics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Kyntra Bio has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

In the previous week, Kyntra Bio had 8 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 9 mentions for Kyntra Bio and 1 mentions for Brainstorm Cell Therapeutics. Kyntra Bio's average media sentiment score of 0.19 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kyntra Bio beats Brainstorm Cell Therapeutics on 12 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, Tevogen Bio had 3 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 4 mentions for Tevogen Bio and 1 mentions for Brainstorm Cell Therapeutics. Tevogen Bio's average media sentiment score of 0.74 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tevogen Bio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$9.50	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.90	N/A

Tevogen Bio presently has a consensus target price of $100.00, suggesting a potential upside of 961.57%. Given Tevogen Bio's higher possible upside, research analysts clearly believe Tevogen Bio is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 70.5% of Tevogen Bio shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-610.37%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Tevogen Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Summary

Brainstorm Cell Therapeutics beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCLI vs. The Competition

Export

Metric	Brainstorm Cell Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.66M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.21	18.47	20.66	25.63
Price / Sales	N/A	294.84	549.87	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	-0.51	6.93	9.93	6.97
Net Income	-$11.62M	$24.11M	$3.55B	$333.62M
7 Day Performance	-0.10%	5.89%	1.71%	1.09%
1 Month Performance	-20.33%	-0.91%	0.49%	3.08%
1 Year Performance	-40.18%	74.58%	39.41%	35.68%

Brainstorm Cell Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCLI Brainstorm Cell Therapeutics	N/A	$0.69 +0.6%	N/A	-39.1%	$7.66M	N/A	N/A	40	News Coverage
SNTI Senti Biosciences	3.1027 of 5 stars	$0.97 -4.9%	$8.50 +776.3%	-67.6%	$30.21M	$20K	N/A	4	News Coverage Positive News Earnings Report
LSTA Lisata Therapeutics	2.1144 of 5 stars	$3.26 flat	$15.00 +360.1%	+41.3%	$29.70M	$170K	N/A	30	Positive News Earnings Report
BCTX Briacell Therap	0.239 of 5 stars	$4.08 -1.9%	N/A	-86.5%	$29.58M	N/A	N/A	8	Short Interest Increase
KYNB Kyntra Bio	0.8411 of 5 stars	$7.22 +6.2%	N/A	N/A	$29.23M	$6.44M	0.16	570	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. SNTI, LSTA, BCTX, KYNB, and TVGN

How does Brainstorm Cell Therapeutics compare to Senti Biosciences?

Summary

How does Brainstorm Cell Therapeutics compare to Lisata Therapeutics?

Summary

How does Brainstorm Cell Therapeutics compare to Briacell Therap?

Summary

How does Brainstorm Cell Therapeutics compare to Kyntra Bio?

Summary

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. SNTI, LSTA, BCTX, KYNB, and TVGN

How does Brainstorm Cell Therapeutics compare to Senti Biosciences?

Does the media prefer BCLI or SNTI?

Is BCLI or SNTI more profitable?

Do analysts recommend BCLI or SNTI?

Do institutionals and insiders believe in BCLI or SNTI?

Which has preferable valuation & earnings, BCLI or SNTI?

Which has more risk & volatility, BCLI or SNTI?

Summary

How does Brainstorm Cell Therapeutics compare to Lisata Therapeutics?

Is BCLI or LSTA more profitable?

Which has preferable valuation & earnings, BCLI or LSTA?

Do analysts recommend BCLI or LSTA?

Do institutionals and insiders believe in BCLI or LSTA?

Does the media prefer BCLI or LSTA?

Which has more risk & volatility, BCLI or LSTA?

Summary

How does Brainstorm Cell Therapeutics compare to Briacell Therap?

Does the media favor BCTX or BCLI?

Do institutionals & insiders have more ownership in BCTX or BCLI?

Which has stronger earnings & valuation, BCTX or BCLI?

Is BCTX or BCLI more profitable?

Which has more volatility and risk, BCTX or BCLI?

Do analysts rate BCTX or BCLI?

Summary

How does Brainstorm Cell Therapeutics compare to Kyntra Bio?

Do insiders and institutionals have more ownership in KYNB or BCLI?

Do analysts recommend KYNB or BCLI?

Which has higher valuation and earnings, KYNB or BCLI?

Is KYNB or BCLI more profitable?

Which has more risk and volatility, KYNB or BCLI?

Does the media refer more to KYNB or BCLI?

Summary

How does Brainstorm Cell Therapeutics compare to Tevogen Bio?

Does the media prefer TVGN or BCLI?

Which has stronger valuation & earnings, TVGN or BCLI?

Do analysts rate TVGN or BCLI?

Do insiders & institutionals hold more shares of TVGN or BCLI?

Is TVGN or BCLI more profitable?

Which has more volatility & risk, TVGN or BCLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools